查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947970

按產品類型、分子類型、分銷管道、最終用戶和給藥方法分類的腸外暴露前預防（PrEP）市場，全球預測，2026-2032年

Parenteral PrEP Market by Product Type, Molecule Type, Distribution Channel, End Users, Regimen - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，注射用 PrEP 市場價值將達到 4.3556 億美元，到 2026 年將成長至 4.9036 億美元，到 2032 年將達到 10.3853 億美元，複合年成長率為 13.21%。

關鍵市場統計數據
基準年 2025 4.3556億美元
預計年份：2026年 4.9036億美元
預測年份 2032 1,038,530,000 美元
複合年成長率 (%) 13.21%

這是一份簡潔且權威的介紹，概述了影響腸外暴露前預防（PrEP）領域的臨床進展、管理創新和決策者優先事項。

注射用PrEP代表了HIV預防領域的模式轉移，它引入了一種長效給藥方式，減輕了患者的用藥負擔，並為不同高危險群提供了更多選擇。本執行摘要總結了近期臨床進展、不斷發展的給藥模式、支付方的考量以及供應鏈趨勢，旨在為決策者制定策略提供簡明扼要的依據。其目標是將複雜的臨床和商業性進展轉化為製造商、醫療系統和專案設計者可操作的方向。

清楚闡述長效藥物、植入式技術和分散式交付模式如何重塑預防策略和服務模式。

腸外暴露前預防（PrEP）領域正經歷變革性的轉變，這主要得益於技術創新、以病人為中心的服務模式以及支付方的調整。長效藥物和植入式系統正在重新定義預防，它們延長了保護期，改變了用藥依從性，並催生了醫療服務中新的接觸點策略。隨著產品特性的演變，人們對監測、診所工作流程以及在醫療服務過渡期間維持保護連續性的機制的期望也在不斷變化。

對 2025 年美國關稅如何迫使製造商和供應鏈領導者重塑其採購、物流和採購策略進行實際分析。

2025年美國關稅的實施進一步增加了注射用PrEP產品全球採購和分銷計劃的複雜性。製造商和經銷商被迫重新評估其籌資策略、供應鏈路線和成本會計框架，以在確保利潤率的同時，維持在不同支付方環境下的產品供應。關稅影響了本地生產、組件採購以及與物流供應商的合約條款等方面的考量，也為更深入評估各國層級的商業風險提供了契機。

基於深度細分的洞察，將產品結構、分子特徵、分銷模式、終端用戶能力和給藥方案與策略決策聯繫起來

按產品、分子、分銷管道、最終用戶和給藥方案進行細分，揭示了腸外暴露前預防（PrEP）生態系統中存在的差異化影響。按產品類型分類，植入式裝置在監管和生命週期管理方面具有獨特的考量，而可生物分解聚合物與不可生物分解聚合物相比，在患者便利性和藥物清除特性方面存在顯著差異。對於長效注射劑，分子特異性的臨床和給藥特性至關重要。卡博特韋和來那卡帕韋各自有特定的給藥持續時間、監測需求和病人諮詢需求。預填充式注射器在某些臨床環境中操作便捷，但需要仔細考慮低溫運輸管理和處置方法。

從全面的區域觀點分析不同監管、支付和醫療服務系統如何影響關鍵區域的採納和准入動態。

區域動態對美洲、歐洲、中東和非洲以及亞太地區的臨床應用路徑、支付方接受度和分銷物流有顯著影響。在美洲，創新治療方法的引入往往透過整合醫療體系和社區計畫來實現，這些體系和計畫優先考慮公平獲取推廣，並有針對性地涵蓋高風險族群。該地區公私支付方並存的格局，既為報銷談判帶來了機遇，也帶來了複雜性，因此更需要建立病患支援機制，以協助病患啟動治療。

公司層面的策略重點在於整合商業化、與支付方合作以及提高生產柔軟性，以推動長效預防解決方案的發展。

注射用PrEP領域的主要企業正在調整其商業化策略和臨床開發計劃，以適應長效植入式技術的特性。策略重點包括建立健全的上市後安全性監測系統，開發病患支援計畫以協助治療的啟動和維持，以及投資提升生產柔軟性以適應多種劑型。藥物研發人員、醫療設備製造商和專業經銷商之間的合作正變得至關重要，這有助於創建整合解決方案，從而簡化臨床工作流程並提高患者依從性。

針對製造商、支付者和醫療服務提供者的實用建議：使證據產生、分發設計和風險緩解與傳播目標保持一致

為了最大限度地發揮腸外暴露前預防（PrEP）的社會和商業性價值，產業領導者應採取多方相關人員的方式，協調臨床開發、報銷策略和分散式服務。首先，將支付方的證據要求納入後期臨床項目，將減少後續環節的摩擦，並加快醫保覆蓋範圍的討論。其次，投資於患者支援基礎設施，例如數位化藥物管理工具、宅配物流和諮詢資源，將有助於在不同的醫療環境中啟動和維持治療。第三，企業和採購方應最佳化其生產和籌資策略，透過地理多元化和策略夥伴關係來降低貿易政策和關稅風險。

對用於得出對相關人員具有實際意義的見解的證據綜合、專家參與和分析方法進行透明的解釋

本研究整合了已發表的臨床文獻、監管指導文件、同行評審研究以及對臨床、支付者和供應鏈專家的訪談，旨在全面了解腸外給藥的暴露前預防（PrEP）生態系統。資料收集優先考慮近期臨床試驗結果、同行評審的安全分析以及能夠揭示實際應用挑戰的實施研究。專家諮詢旨在了解醫院、社區診所、專科診所和分銷合作夥伴的運作實際情況，從而提供關於推廣應用障礙和促進因素的實證觀點。

綜合結論概述了整合臨床創新、分銷韌性和相關人員合作以推進預防工作的策略要務。

長效注射劑和植入式裝置的融合、不斷演變的分銷模式以及複雜的支付環境，共同促成了腸外暴露前預防（PrEP）應用的一個關鍵時刻。決策者必須仔細考慮產品的特定臨床考量、通路選擇和區域監管環境，同時也要因應貿易政策變化所帶來的供應鏈風險增加。然而，協調臨床、營運和商業性策略，將為擴大PrEP的可及性、減輕用藥負擔以及為高風險族群提供多樣化的預防選擇帶來巨大潛力。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的腸外暴露前預防市場

  • 植入式醫療器材
    • 可生物分解聚合物
    • 不可生物分解聚合物
  • 長效注射劑
    • 卡博特格拉維爾
    • 莉娜·卡帕大廈
  • 預填充式注射器

9. 依分子類型分類的腸外暴露前預防市場

  • 卡博特格拉維爾
  • 莉娜·卡帕大廈

10. 按分銷管道分類的腸外PrEP市場

  • 直接面向患者的計劃
    • 宅配服務
    • 郵購
  • 醫院藥房
  • 零售藥房
  • 專科診所
    • 社區醫療中心
    • 感染疾病診所

11. 依最終使用者分類的腸外暴露前預防市場

  • 社區醫療中心
    • 地區
    • 都市區
  • 愛滋病診所
  • 研究中心
    • 學術機構
    • 私人研究機構

12. 依給藥途徑分類的腸外暴露前預防市場

  • 隨選管理
  • 常規管理

13. 按地區分類的腸外暴露前預防市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 按組別分類的腸外暴露前預防市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國腸外暴露前預防市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國腸外暴露前預防市場

17. 中國：注射用PrEP市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6B4

The Parenteral PrEP Market was valued at USD 435.56 million in 2025 and is projected to grow to USD 490.36 million in 2026, with a CAGR of 13.21%, reaching USD 1,038.53 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 435.56 million
Estimated Year [2026] USD 490.36 million
Forecast Year [2032] USD 1,038.53 million
CAGR (%) 13.21%

Concise and authoritative introduction framing clinical progress, delivery innovation, and decision-maker priorities shaping the parenteral PrEP landscape

Parenteral pre-exposure prophylaxis (PrEP) represents a paradigm shift in HIV prevention, introducing long-acting modalities that reduce adherence burdens and expand choices for diverse populations at risk. This executive summary synthesizes recent clinical advances, evolving delivery models, payer considerations, and supply chain dynamics to offer decision-makers a concise foundation for strategy development. The aim is to translate complex clinical and commercial developments into actionable direction for manufacturers, health systems, and program designers.

Over the past several years, injectable and implantable platforms have matured from investigational concepts to clinically validated alternatives to daily oral regimens. As a result, stakeholders face new questions about patient selection, service delivery networks, and integration with existing prevention infrastructures. This section sets the stage for deeper analysis, emphasizing the intersection of scientific progress with pragmatic implementation considerations and highlighting how evidence, regulation, and patient preference collectively shape uptake trajectories.

Clear articulation of how long-acting agents, implantable technologies, and decentralized delivery paradigms are reshaping prevention strategies and service models

The landscape for parenteral PrEP is undergoing transformative shifts driven by technological innovation, patient-centered delivery models, and payer adaptation. Long-acting agents and implantable systems are redefining prophylaxis by extending protection windows, thereby altering adherence dynamics and enabling novel touchpoint strategies within healthcare delivery. As product profiles evolve, so too do expectations for monitoring, clinic workflows, and mechanisms to maintain continuity of protection during care transitions.

Concurrently, distribution channels are diversifying to accommodate decentralized care, with direct-to-patient programs and specialty clinic partnerships becoming central to reach underserved populations. Regulatory clarity around long-acting formulations and implantable devices is improving, prompting manufacturers to prioritize lifecycle planning and post-market surveillance. Taken together, these shifts necessitate integrated commercial strategies that align clinical value propositions with operational realities and sustainable reimbursement pathways.

Practical analysis of how US tariff measures enacted in 2025 have compelled manufacturers and supply chain leaders to reconfigure sourcing, logistics, and procurement tactics

The introduction of tariffs in the United States in 2025 has layered additional complexity onto global procurement and distribution planning for parenteral PrEP products. Manufacturers and distributors have had to reassess sourcing strategies, supply chain routing, and costing frameworks to preserve margins while maintaining access across varied payer landscapes. The tariffs influence considerations around local manufacturing, component sourcing, and contractual terms with logistics providers, prompting a more granular evaluation of country-level operational risk.

In response, supply chain teams are prioritizing resilience through diversified supplier networks, nearshoring of critical components, and contractual hedges that mitigate the impact of trade policy volatility. Health systems and procurement entities are likewise examining procurement windows and inventory policies to buffer short-term cost fluctuations. Ultimately, the tariff environment has underscored the importance of flexible manufacturing strategies and collaborative contracting as prerequisites for sustaining dependable access to long-acting prevention modalities.

Deep segmentation-driven insights connecting product architectures, molecule attributes, distribution models, end-user capacities, and dosing regimens to strategic decisions

Insights drawn from product, molecule, distribution channel, end-user, and regimen segmentation reveal differentiated implications across the parenteral PrEP ecosystem. When viewed by product type, implantable devices present unique device-regulatory and lifecycle management considerations, with biodegradable polymers offering distinct patient convenience and removal profiles compared with non-biodegradable polymers. Long-acting injectables foreground molecule-specific clinical and dosing characteristics, where cabotegravir and lenacapavir each carry particular administration windows, monitoring expectations, and patient counseling requirements. Prefilled syringes add operational simplicity for some clinical settings but require attention to cold chain and disposal practices.

Examining segmentation by molecule type highlights how cabotegravir and lenacapavir demand bespoke clinical pathways, pharmacovigilance programs, and education initiatives to ensure appropriate patient selection. Distribution channel segmentation indicates that direct-to-patient programs, including home delivery and mail order, can expand reach and convenience, while hospital and retail pharmacies remain pivotal for integration with broader care services. Specialty clinics, comprising community health centers and infectious disease clinics, serve as critical hubs for initiation and follow-up. End-user segmentation underscores differing operational environments: community health centers, both rural and urban, must balance resource constraints and local outreach; HIV clinics focus on clinical continuity and complex case management; research centers, spanning academic institutions and private research organizations, continue to inform best practices. Finally, regimen segmentation separates on-demand dosing, including post-exposure-only and pre-exposure-only approaches, from periodic dosing schedules such as two-month and three-month intervals, each of which shapes adherence support, visit cadence, and refill logistics. Integrating these segmentation perspectives enables stakeholders to tailor product development, distribution strategies, and patient engagement to the nuanced needs of target populations and delivery environments.

Comprehensive regional perspective on how differing regulatory, payer, and delivery ecosystems across major geographies influence rollout and access dynamics

Regional dynamics exert a powerful influence on clinical adoption pathways, payer receptivity, and distribution logistics across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, innovation adoption tends to be channeled through integrated health systems and community-based programs that prioritize equitable access and targeted outreach to populations with elevated risk profiles. The combination of private and public payers in this region creates both opportunities and complexity for reimbursement negotiations and further necessitates patient assistance mechanisms to support initiation.

In Europe, Middle East & Africa, regulatory heterogeneity and variable infrastructure necessitate adaptable deployment models, with some markets favoring centralized procurement and others relying on local programmatic delivery. Regional philanthropic initiatives and multilateral partnerships continue to play a role in accelerating access in resource-constrained settings. Moving to Asia-Pacific, diverse regulatory pathways and manufacturing capacity present opportunities for regional production partnerships and technology transfer, while varying healthcare delivery models drive differentiated uptake patterns. Across all regions, tailored engagement with payers, policymakers, and community stakeholders remains essential to align commercial plans with public health objectives and to ensure that innovations translate into sustained access.

Strategic company-level priorities emphasizing integrated commercialization, payer engagement, and manufacturing flexibility to advance long-acting prevention solutions

Leading companies active in the parenteral PrEP space are aligning clinical development plans with commercialization tactics that reflect the unique characteristics of long-acting agents and implantable technologies. Strategic priorities include establishing robust post-market safety surveillance, developing patient support programs that address initiation and continuation, and investing in manufacturing flexibility to support multiple delivery formats. Partnerships between pharmaceutical developers, device manufacturers, and specialty distributors are becoming central to creating integrated offerings that streamline clinic workflows and support patient adherence.

Corporate strategies also emphasize payer engagement early in development to clarify evidence needs for coverage determinations, and to design value demonstrations that quantify health system benefits beyond simple clinical endpoints. In parallel, companies are exploring differentiated service models-such as bundled service agreements for clinics or subscription-based supply arrangements-to reduce friction in adoption. Collectively, these initiatives reflect a shift from product-only commercialization toward solutions that blend clinical efficacy, operational simplicity, and payer-aligned value propositions.

Action-oriented recommendations for manufacturers, payers, and providers to align evidence generation, distribution design, and risk mitigation with adoption goals

Industry leaders should adopt a multi-stakeholder approach that synchronizes clinical development, reimbursement strategy, and decentralized delivery to maximize the societal and commercial value of parenteral PrEP. First, embedding payer evidence requirements into late-stage clinical programs will reduce downstream friction and accelerate coverage conversations. Second, investing in patient support infrastructure-digital adherence tools, home delivery logistics, and counseling resources-will ease initiation and retention across diverse care settings. Third, companies and purchasers should closely examine manufacturing and sourcing strategies to mitigate trade policy and tariff risks through geographic diversification and strategic partnerships.

Operationally, aligning distribution strategies with the capacities of hospitals, specialty clinics, and community health centers will be critical; direct-to-patient programs should be piloted alongside traditional channels to evaluate real-world adherence and patient satisfaction. In addition, collaborative pilots with public health authorities can validate integration pathways and build evidence for broader adoption. Executing these recommendations will require cross-functional coordination, near-term investments in infrastructure, and ongoing engagement with community stakeholders to ensure equitable access and sustained uptake.

Transparent explanation of the evidence synthesis, expert engagement, and analytic approaches used to derive pragmatic insights for stakeholders

This research synthesizes publicly available clinical literature, regulatory guidance documents, peer-reviewed studies, and primary interviews with clinical, payer, and supply chain experts to construct a holistic view of the parenteral PrEP ecosystem. Data collection prioritized recent clinical trial results, peer-reviewed safety analyses, and implementation studies that illuminate real-world delivery challenges. Expert consultations were structured to capture operational realities across hospitals, community clinics, specialty providers, and distribution partners, providing grounded perspectives on adoption barriers and enablers.

Analytic methods combined qualitative thematic synthesis with scenario-based operational assessment to identify strategic inflection points for stakeholders. Where applicable, findings were triangulated across multiple evidence streams to enhance robustness. The methodology emphasizes transparency in data sourcing and acknowledges limitations where evidence remains emergent, particularly for novel implantable technologies and long-term safety profiles, while prioritizing actionable implications for commercial and public health decision-making.

Integrated conclusion summarizing strategic imperatives for aligning clinical innovation, distribution resilience, and stakeholder collaboration to advance prevention

The convergence of long-acting injectables and implantable devices, evolving distribution models, and complex payer environments creates a pivotal moment for parenteral PrEP implementation. Decision-makers must navigate product-specific clinical considerations, distribution channel choices, and regional regulatory landscapes while managing supply chain risks heightened by trade policy shifts. Nevertheless, the potential to expand access, reduce adherence burden, and diversify prevention options for at-risk populations is substantial when strategies are aligned across clinical, operational, and commercial dimensions.

Moving forward, sustained collaboration among developers, health systems, payers, and community organizations will be essential to translate technical advances into durable public health impact. By focusing on evidence generation that resonates with payers, investing in flexible supply chain and distribution solutions, and centering patient experience in delivery design, stakeholders can accelerate responsible adoption and ensure long-acting prophylaxis becomes an accessible option for those who will benefit most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Parenteral PrEP Market, by Product Type

  • 8.1. Implantable Device
    • 8.1.1. Biodegradable Polymers
    • 8.1.2. Non-Biodegradable Polymers
  • 8.2. Long-Acting Injectable
    • 8.2.1. Cabotegravir
    • 8.2.2. Lenacapavir
  • 8.3. Prefilled Syringes

9. Parenteral PrEP Market, by Molecule Type

  • 9.1. Cabotegravir
  • 9.2. Lenacapavir

10. Parenteral PrEP Market, by Distribution Channel

  • 10.1. Direct-To-Patient Programs
    • 10.1.1. Home Delivery
    • 10.1.2. Mail Order
  • 10.2. Hospital Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Clinics
    • 10.4.1. Community Health Centers
    • 10.4.2. Infectious Disease Clinics

11. Parenteral PrEP Market, by End Users

  • 11.1. Community Health Centers
    • 11.1.1. Rural Centers
    • 11.1.2. Urban Centers
  • 11.2. HIV Clinics
  • 11.3. Research Centers
    • 11.3.1. Academic Institutions
    • 11.3.2. Private Research Organizations

12. Parenteral PrEP Market, by Regimen

  • 12.1. On-Demand Dosing
  • 12.2. Periodic Dosing

13. Parenteral PrEP Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Parenteral PrEP Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Parenteral PrEP Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Parenteral PrEP Market

17. China Parenteral PrEP Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Accord Healthcare Inc.
  • 18.6. Amneal Pharmaceuticals, Inc.
  • 18.7. Aurobindo Pharma Ltd.
  • 18.8. Cipla Ltd.
  • 18.9. Dr. Reddy's Laboratories Ltd.
  • 18.10. Fresenius Kabi AG
  • 18.11. Gilead Sciences, Inc.
  • 18.12. Hetero Labs Limited
  • 18.13. Lupin Limited
  • 18.14. Merck & Co., Inc.
  • 18.15. Mylan N.V.
  • 18.16. Sun Pharmaceutical Industries Ltd.
  • 18.17. Teva Pharmaceutical Industries Ltd.
  • 18.18. Viatris Inc.
  • 18.19. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PARENTERAL PREP MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PARENTERAL PREP MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PARENTERAL PREP MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PARENTERAL PREP MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PARENTERAL PREP MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PARENTERAL PREP MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PARENTERAL PREP MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PARENTERAL PREP MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PARENTERAL PREP MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PARENTERAL PREP MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PARENTERAL PREP MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PARENTERAL PREP MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PARENTERAL PREP MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PARENTERAL PREP MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOME DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOME DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOME DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PARENTERAL PREP MARKET SIZE, BY MAIL ORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PARENTERAL PREP MARKET SIZE, BY MAIL ORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PARENTERAL PREP MARKET SIZE, BY MAIL ORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARENTERAL PREP MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PARENTERAL PREP MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARENTERAL PREP MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PARENTERAL PREP MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PARENTERAL PREP MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PARENTERAL PREP MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PARENTERAL PREP MARKET SIZE, BY RURAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PARENTERAL PREP MARKET SIZE, BY RURAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PARENTERAL PREP MARKET SIZE, BY RURAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PARENTERAL PREP MARKET SIZE, BY URBAN CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PARENTERAL PREP MARKET SIZE, BY URBAN CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PARENTERAL PREP MARKET SIZE, BY URBAN CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PARENTERAL PREP MARKET SIZE, BY HIV CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PARENTERAL PREP MARKET SIZE, BY HIV CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARENTERAL PREP MARKET SIZE, BY HIV CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PARENTERAL PREP MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PARENTERAL PREP MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PARENTERAL PREP MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRIVATE RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRIVATE RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRIVATE RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PARENTERAL PREP MARKET SIZE, BY ON-DEMAND DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PARENTERAL PREP MARKET SIZE, BY ON-DEMAND DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PARENTERAL PREP MARKET SIZE, BY ON-DEMAND DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PARENTERAL PREP MARKET SIZE, BY PERIODIC DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PARENTERAL PREP MARKET SIZE, BY PERIODIC DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PARENTERAL PREP MARKET SIZE, BY PERIODIC DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PARENTERAL PREP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PARENTERAL PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL PARENTERAL PREP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 201. GCC PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 237. G7 PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 240. G7 PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. G7 PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 249. NATO PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. NATO PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)